Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

Brain

Volumn 140, Issue 5, 2017, Pages 1220-1230

  Nisbet, Rebecca M ^a   Van Der Jeugd, Ann ^a,b   Leinenga, Gerhard ^a   Evans, Harrison T ^a   Janowicz, Phillip W ^a   Götz, Jürgen ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alzheimer's disease; blood brain barrier; dementia; neurofibrillary tangles; tau

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; RN2N ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; ISOPROTEIN;

ADJUVANT THERAPY; ALZHEIMER DISEASE; AMYGDALA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BLOOD BRAIN BARRIER; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; FEMALE; MOUSE; MOUSE MODEL; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; TREATMENT OUTCOME; ULTRASOUND THERAPY; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; MAZE TEST; METABOLISM; MULTIMODALITY CANCER THERAPY; NERVE CELL; PHOSPHORYLATION; PROCEDURES; PSYCHOLOGY; TAUOPATHIES;

ANIMALS; ANTIBODIES; BRAIN; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; MAZE LEARNING; MICE; MICE, TRANSGENIC; NEURONS; PHOSPHORYLATION; PROTEIN ISOFORMS; TAU PROTEINS; TAUOPATHIES; ULTRASONIC THERAPY;

EID: 85019548685     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awx052     Document Type: Article

References (45)

1. Afadzi M, Strand SP, Nilssen EA, Masoy SE, Johansen TF, Hansen R, et al. Mechanisms of the ultrasound-mediated intracellular delivery of liposomes and dextrans. IEEE Trans Ultrason Ferroelectr Freq Control 2013; 60: 21-33.
2. Alonso A, Reinz E, Fatar M, Jenne J, Hennerici MG, Meairs S. Neurons but not glial cells overexpress ubiquitin in the rat brain following focused ultrasound-induced opening of the blood-brain barrier. Neuroscience 2010; 169: 116-24.
3. Amniai L, Lippens G, Landrieu I. Characterization of the AT180 epitope of phosphorylated Tau protein by a combined nuclear magnetic resonance and fluorescence spectroscopy approach. Biochem Biophys Res Commun 2011; 412: 743-6.
4. Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 1992; 11: 1593-7.
5. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011; 118: 658-67.
6. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 2014; 34: 4260-72.
7. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM. Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2011; 6: e18296.
8. Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 2003; 278: 187-93.
9. Choi JJ, Wang S, Tung YS, Morrison B III, Konofagou EE. Molecules of various pharmacologically-relevant sizes can cross the ultrasoundinduced blood-brain barrier opening in vivo. Ultrasound Med Biol 2010; 36: 58-67.
10. Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 2014; 137: 2834-46.
11. Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem 2013; 288: 35452-65.
12. Deters N, Ittner LM, Gotz J. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci 2008; 28: 137-47.
13. Fernandez-Funez P, Zhang Y, Sanchez-Garcia J, de Mena L, Khare S, Golde TE, et al. Anti-A beta single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease. Hum Mol Genet 2015; 24: 6093-105.
14. Ferrer-Miralles N, Corchero JL, Kumar P, Cedano JA, Gupta KC, Villaverde A, et al. Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microb Cell Fact 2011; 10: 101.
15. Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 1990; 9: 4225-30.
16. Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J 1994; 301 (Pt 3): 871-7.
17. Golde TE. Open questions for Alzheimer's disease immunotherapy. Alzheimers Res Ther 2014; 6: 3.
18. Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001; 276: 529-34.
19. Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 2013; 288: 33081-95.
20. Hanger DP, Noble W. Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis 2011; 2011: 352805.
21. Hernandez F, Lucas JJ, Avila J. GSK3 and tau: two convergence points in Alzheimer's disease. J Alzheimers Dis 2013; 33 (Suppl 1): S141-4.
22. Ising C, Stanley M, Holtzman DM. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Clin Pharmacol Ther 2015; 98: 469-71.
23. Ittner A, Bertz J, Suh LS, Stevens CH, Gotz J, Ittner LM. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem 2015; 132: 135-45.
24. Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, Li KM, et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci USA 2008; 105: 15997-6002.
25. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-97.
26. Johnson S, Bird RE. Construction of single-chain Fv derivatives monoclonal antibodies and their production in Escherichia coli. Methods Enzymol 1991; 203: 88-98.
27. Jones ML, Seldon T, Smede M, Linville A, Chin DY, Barnard R, et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. J Immunol Methods 2010; 354: 85-90.
28. Jordao JF, Ayala-Grosso CA, Markham K, Huang Y, Chopra R, McLaurin J, et al. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS One 2010; 5: e10549.
29. Kohler C, Dinekov M, Gotz J. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice. Neurobiol Aging 2013; 34: 1369-79.
30. Koss DJ, Robinson L, Drever BD, Plucinska K, Stoppelkamp S, Veselcic P, et al. Mutant Tau knock-in mice display frontotemporal dementia relevant behaviour and histopathology. Neurobiol Dis 2016; 91: 105-23.
31. Krishnaswamy S, Lin Y, Rajamohamedsait WJ, Rajamohamedsait HB, Krishnamurthy P, Sigurdsson EM. Antibody-derived in vivo imaging of tau pathology. J Neurosci 2014; 34: 16835-50.
32. Leinenga G, Gotz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer's disease mouse model. Sci Transl Med 2015; 7: 278ra33.
33. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J 2006; 20: 2576-8.
34. Liu C, Gotz J. Profiling murine tau with 0N, 1N and 2N isoformspecific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus. PLoS One 2013; 8: e84849.
35. Liu C, Song X, Nisbet R, Gotz J. Co-immunoprecipitation with tau isoform-specific antibodies reveals distinct protein interactions, and highlights a putative role for 2N tau in disease. J Biol Chem 2016a; 291: 8173-88.
36. Liu HL, Hsu PH, Lin CY, Huang CW, Chai WY, Chu PC, et al. Focused ultrasound enhances central nervous system delivery of Bevacizumab for Malignant Glioma treatment. Radiology 2016b; 281: 99-108.
37. Nisbet RM, Nigro J, Breheney K, Caine J, Hattarki MK, Nuttall SD. Central amyloid-beta-specific single chain variable fragment ameliorates Abeta aggregation and neurotoxicity. Protein Eng Des Sel 2013; 26: 571-80.
38. Nisbet RM, Polanco JC, Ittner LM, Gotz J. Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol 2015; 129: 207-20.
39. Pennanen L, Welzl H, D'Adamo P, Nitsch RM, Gotz J. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol Dis 2004; 15: 500-9.
40. Porter VR, Buxton WG, Fairbanks LA, Strickland T, O'Connor SM, Rosenberg-Thompson S, et al. Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. J Neuropsychiatry Clin Neurosci 2003; 15: 180-6.
41. Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One 2014; 9: e96801.
42. Vazquez E, Ferrer-Miralles N, Villaverde A. Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today 2008; 13: 1067-74.
43. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007; 2: 322-8.
44. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006; 26: 5340-6.
45. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013; 80: 402-14.